Skip to Main Content

Hello, everyone, and top of the morning to you. And a fine one it is, despite expectations for a spot of snow. After all, the weather is a mere distraction when one is busy foraging for items of interest. Moreover, we are preparing to run yet another panel on a fascinating topic. Feel free to stop by this evening if you happen to be in the neighborhood. Meanwhile, time to get cracking. Here is the usual menu of tidbits to help you on your journey today. Hope all goes well and, as always, please do keep in touch. We appreciate your tips and insights …

Novartis (NVS) denied a report in a Swiss newspaper that it plans to split off its Sandoz generics unit, according to Reuters. A Novartis spokesman called the newspaper report “speculation. We’re completely committed to the Sandoz business, and we’re looking at transforming it and making it as strong as it can be in the global generics business.” The drug maker recently agreed to sell parts of its Sandoz unit for up to $1 billion to Aurobindo Pharma as part of a plan to focus on higher-growth areas, such as more complex generic medicines and biosimilars.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!